ClinicalTrials.gg
CompletedNCT02994056Updated Mar 2, 2020Results posted

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

A Phase 2 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
71st of 94
32 · median 75
Started
2017
with 10 others
Phase 2
31 of 94
none open now
Registered
58th of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 71st largest by enrollment, is one of 11 that started in 2017, is one of 31 in phase 2, and was the 58th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) Class C cirrhosis.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A (BMI) of ≥ 18 kg/m\^2
  • Chronic infection (≥ 6 months) as documented by either prior medical history or liver
  • Quantifiable HCV RNA at screening
  • Individuals may be non-transplanted or with recurrent HCV post-liver transplant.

    • If listed for liver transplant, then the projected date of transplant must be ≥12 weeks after Day1 of treatment
    • If post-liver transplant, then Day1 must be ≥ 6 months from date of transplant
  • CPT score of 10 to 12, inclusive, as determined at screening
  • Liver imaging within 6 months of Day 1 to exclude hepatocellular carcinoma (HCC)
  • If treatment-experienced, the most recent HCV treatment must have been completed at least 8 weeks prior to Screening
  • Females of must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 prior to randomization
  • Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of
  • Females must agree to refrain from egg donation and in vitro fertilization during treatment until at least 30 days after the last dose of SOF/VEL or 6 months after the last dose of RBV, whichever occurs last
  • Lactating females must agree to discontinue nursing before the study drugs are administered
  • Males must agree to refrain from sperm donation from the date of screening until at least 7 months after the last dose of RBV or 30 days after the last dose of SOF/VEL, whichever occurs last
  • Adults must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments

Key Exclusion Criteria:

  • Current or prior history of any of the following:

    • medical or psychiatric illness or individual is currently under evaluation for a potentially clinically significant illness
    • Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug
    • Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
    • Significant pulmonary disease, significant cardiac disease or porphyria
    • within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc.). Adults under evaluation for possible malignancy are not eligible
    • Significant drug allergy (such as anaphylaxis or hepatotoxicity)
  • Any history of organ transplant other than liver or kidney
  • Chronic liver disease of a non-HCV etiology
  • Inability to exclude HCC by imaging within 6 months of Day 1
  • Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
  • Active spontaneous bacterial peritonitis at screening
  • Infection requiring systemic antibiotics at the time of screening
  • Evidence of fibrosing cholestatic hepatitis at screening
  • Life threatening serious adverse event (SAE) during screening
  • Active variceal bleeding within 6 months of screening
  • Prior placement of a portosystemic shunt (such as TIPS)
  • with clinically significant abnormalities
  • Laboratory parameters with clinically significant abnormalities
  • surface antigen positive at screening
  • Infection with (HIV)
  • Clinically-relevant alcohol or drug abuse within 12 months of screening. A positive drug screen will exclude individuals unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the Investigator
  • Prior exposure to any HCV Non-structural Protein 5A (NS5A) inhibitor
  • Current use of at any dose >10 mg of prednisone/day (or equivalent dose of corticosteroid)
  • Use of any prohibited concomitant medications
  • Use of granulocyte macrophage colony-stimulating factor (GM-CSF), epoetin alfa or other hematopoietic stimulating agents within 2 weeks of screening
  • Male with pregnant female partner
  • History of clinically significant hemoglobinopathy (eg, sickle cell disease, thalassemia)
  • to RBV therapy
  • Known to VEL, RBV, SOF, the metabolites, or formulation
  • Participation in a clinical study with an drug or biologic within 3 months prior to Day 1

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    SOF/VEL+ RBV

    SOF/VEL FDC plus RBV for 12 weeks

    Drug: SOF/VEL · Drug: RBV

Interventions

  • DrugSOF/VEL

    Drug pages: Sofosbuvir · Velpatasvir

    400/100 mg FDC tablet administered orally once daily

    Also known as: Epclusa®, GS-7977/GS-5816

  • DrugRBV

    Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Study Drug (SOF/VEL or RBV) Due to an Adverse Event

    Time frame: First dose date up to Week 12

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)

    SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

    Time frame: Posttreatment Week 24

  3. Percentage of Participants With HCV RNA < LLOQ While on Study Treatment

    Time frame: Weeks 2, 4, 8, and 12

  4. Percentage of Participants With No Change, Improved, and Worsened Child-Pugh-Turcotte (CPT) Class

    CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. Participants with no change CPT class was defined as having CPT Class same between Baseline and Posttreatment Week 24.

    Time frame: Baseline to Posttreatment Week 24

  5. Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score

    MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.

    Time frame: Baseline to Posttreatment Week 24

  6. Absolute HCV RNA Level Through Week 12

    Time frame: Baseline; Weeks 2, 4, 8, and 12

  7. Change From Baseline in HCV RNA

    Time frame: Baseline; Weeks 2, 4, 8, and 12

  8. Number of Participants With Virologic Failure

    Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit

    Time frame: Baseline up to Posttreatment Week 24

07

Results

Posted Oct 8, 2019

Participant flow

Participants were enrolled at study sites in the United States and France. The first participant was screened on 23 January 2017. The last study visit occurred on 12 December 2018.

Participant flow — Overall Study
MilestoneSOF/VEL+ RBV
Started32
Completed23
Not completed9
Withdrew: Death8
Withdrew: Withdrew consent1

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsSOF/VEL+ RBV (Total)SOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)78.1 (60.0 to 90.7)72.2 (46.5 to 90.3)80.0 (28.4 to 99.5)85.7 (42.1 to 99.6)
PrimaryPercentage of Participants Who Permanently Discontinued Study Drug (SOF/VEL or RBV) Due to an Adverse Event
Time frame:
First dose date up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Study Drug (SOF/VEL or RBV) Due to an Adverse Event
percentage of participantsSOF/VEL+ RBV
Discontinuation of SOF/VEL6.3
Discontinuation of RBV21.9
SecondaryPercentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participantsSOF/VEL+ RBV (Total)SOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)
Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)87.5 (71.0 to 96.5)88.9 (65.3 to 98.6)80.0 (28.4 to 99.5)85.7 (42.1 to 99.6)
SecondaryPercentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)

SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame:
Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)
percentage of participantsSOF/VEL+ RBV (Total)SOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)
Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)75.0 (56.6 to 88.5)72.2 (46.5 to 90.3)80.0 (28.4 to 99.5)71.4 (29.0 to 96.3)
SecondaryPercentage of Participants With HCV RNA < LLOQ While on Study Treatment
Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With HCV RNA < LLOQ While on Study Treatment
Percentage of participantsSOF/VEL+ RBV (Total)SOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)
Week 243.8 (26.4 to 62.3)38.9 (17.3 to 64.3)0 (0.0 to 52.2)71.4 (29.0 to 96.3)
Week 496.6 (82.2 to 99.9)100.0 (79.4 to 100.0)75.0 (19.4 to 99.4)100.0 (59.0 to 100.0)
Week 8100.0 (88.1 to 100.0)100.0 (79.4 to 100.0)100.0 (39.8 to 100.0)100.0 (59.0 to 100.0)
Week 12100.0 (88.1 to 100.0)100.0 (79.4 to 100.0)100.0 (39.8 to 100.0)100.0 (59.0 to 100.0)
SecondaryPercentage of Participants With No Change, Improved, and Worsened Child-Pugh-Turcotte (CPT) Class

CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. Participants with no change CPT class was defined as having CPT Class same between Baseline and Posttreatment Week 24.

Time frame:
Baseline to Posttreatment Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With No Change, Improved, and Worsened Child-Pugh-Turcotte (CPT) Class
Percentage of participantsSOF/VEL+ RBV
Improved CPT Class42.1
Worsened CPT Class0
No Change CPT Class57.9
SecondaryPercentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score

MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.

Time frame:
Baseline to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score
percentage of participantsSOF/VEL+ RBV
Decrease (Improvement)52.6
No Change21.1
Increase (Worsening)26.3
SecondaryAbsolute HCV RNA Level Through Week 12
Time frame:
Baseline; Weeks 2, 4, 8, and 12
Reported as:
Mean · log10 IU/mL
Absolute HCV RNA Level Through Week 12
log10 IU/mLSOF/VEL+ RBV (Total)SOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)
Baseline5.17 ± 1.1875.46 ± 0.5376.01 ± 0.5024.84 ± 1.058
Week 21.46 ± 0.3921.47 ± 0.3871.63 ± 0.1501.43 ± 0.526
Week 41.15 ± 0.001.15 ± 0.0001.15 ± 0.0001.15 ± 0.000
Week 81.15 ± 0.001.15 ± 0.0001.15 ± 0.0001.15 ± 0.000
Week 121.15 ± 0.001.15 ± 0.0001.15 ± 0.0001.15 ± 0.000
SecondaryChange From Baseline in HCV RNA
Time frame:
Baseline; Weeks 2, 4, 8, and 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA
log10 IU/mLSOF/VEL+ RBV (Total)SOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)
Change at Week 2-3.72 ± 1.092-4.06 ± 0.531-4.50 ± 0.366-3.41 ± 0.665
Change at Week 4-3.99 ± 1.238-4.39 ± 0.520-4.88 ± 0.395-3.70 ± 1.058
Change at Week 8-4.00 ± 1.217-4.39 ± 0.520-4.72 ± 0.445-3.70 ± 1.058
Change at Week 12-4.00 ± 1.217-4.39 ± 0.520-4.72 ± 0.445-3.70 ± 1.058
SecondaryNumber of Participants With Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit

Time frame:
Baseline up to Posttreatment Week 24
Reported as:
Count of participants · Participants
Number of Participants With Virologic Failure
ParticipantsSOF/VEL+ RBV (GT-1)SOF/VEL+ RBV (GT-2)SOF/VEL+ RBV (GT-3)SOF/VEL+ RBV (Total)
Number of Participants With Virologic Failure0011

Adverse events

Collected over Adverse Events: First dose date up to Week 12 plus 30 days; All-Cause Mortality: First dose date up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOF/VEL+ RBV8/32 (25%)17/32 (53.1%)27/32 (84.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventSOF/VEL+ RBV
SepsisInfections and infestations2/32
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/32
Hepatic hydrothoraxRespiratory, thoracic and mediastinal disorders2/32
Atrial fibrillationCardiac disorders1/32
Ventricular tachycardiaCardiac disorders1/32
AscitesGastrointestinal disorders1/32
Gastrointestinal haemorrhageGastrointestinal disorders1/32
Oedema peripheralGeneral disorders1/32
PyrexiaGeneral disorders1/32
Dermo-hypodermitisInfections and infestations1/32
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSOF/VEL+ RBV
AnaemiaBlood and lymphatic system disorders8/32
NauseaGastrointestinal disorders8/32
AstheniaGeneral disorders6/32
VomitingGastrointestinal disorders5/32
AscitesGastrointestinal disorders3/32
ConstipationGastrointestinal disorders3/32
DiarrhoeaGastrointestinal disorders3/32
Muscle spasmsMusculoskeletal and connective tissue disorders3/32
HeadacheNervous system disorders3/32
Abdominal painGastrointestinal disorders2/32

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)SOF/VEL+ RBV
Mean55 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)SOF/VEL+ RBV
Female6
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SOF/VEL+ RBV
Hispanic or Latino7
Not Hispanic or Latino19
Unknown or Not Reported6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOF/VEL+ RBV
American Indian or Alaska Native1
Black or African American Native6
White18
Not Permitted6
Other1
Region of Enrollment
Region of Enrollment(participants)SOF/VEL+ RBV
United States26
France6
HCV RNA
HCV RNA(log10 IU/mL)SOF/VEL+ RBV
Mean5.2 ± 1.19
HCV RNA Category
HCV RNA Category(Participants)SOF/VEL+ RBV
< 800,000 IU/mL23
≥ 800,000 IU/mL9
IL28B
IL28B(Participants)SOF/VEL+ RBV
CC15
CT14
TT3

2 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Tampa General Medical Group
    Tampa, Florida 33606, United States
  • Northwestern Memorial Hospital; Clinical Research Unit
    Chicago, Illinois 60611, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • Southern Therapy and Advanced Research LLC
    Jackson, Mississippi 39216, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Intermountain Liver Disease and Transplant Center
    Murray, Utah 84107, United States
  • Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia
    Richmond, Virginia 23226, United States
  • University of Washington/ Harborview Medical Center
    Seattle, Washington 98105, United States
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Hopital Paul Brousse
    Villejuif, 94800, France
09

References and documents

Publications

  • Flamm S, Lawitz E, Borg B, Charlton M, Landis C, Reddy R, et al. High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis [Poster THU-138]. EASL: The International Liver Congress; 2019 10-14 April; Vienna, Austria.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2018, 20 months.

Results were first posted in Oct 2019, 1 year after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 20 months is above that.

Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 15, 2016
StartActual
Jan 23, 2017
Primary completionActual
Sep 25, 2018
CompletionActual
Dec 12, 2018
Results first posted
Oct 8, 2019
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02994056
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Jan 23, 2017
Primary completion
Sep 25, 2018
Completion
Dec 12, 2018
Results posted
Oct 8, 2019
Last update
Mar 2, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Ribavirin

Start the discussion